A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Digoxin (LANOXIN)

1 INDICATIONS & USAGE Digoxin is a cardiac glycoside indicated for: Treatment of mild to moderate heart failure in adults. ( 1.1 ) Increasing myocardial contractility in pediatric patients with hea....

First FDA approval1975-10-24
Generic availableYes · 10 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$55.2M in CY2024 Part D spend2.3M claims · 665K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.113/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.116
Across all dosage forms in distribution.
Highest NADAC
$0.135
Range is tight.
Plans with PA
12 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Digoxin used for?

1 INDICATIONS & USAGE Digoxin is a cardiac glycoside indicated for: Treatment of mild to moderate heart failure in adults. ( 1.1 ) Increasing myocardial contractility in pediatric patients with hea....

Is there a generic for Digoxin?

Yes. 18 ANDAs filed at FDA, 10 generic manufacturers currently shipping.

How much does my plan pay for Digoxin?

Across 329 Part D plans, Digoxin averages $0.116/unit (NADAC). Lowest available: $0.113/unit. Highest in distribution: $0.135/unit.

Is Digoxin on the FDA shortage list?

No. Digoxin is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.